Categories Earnings Calls, Other Industries

FedEx Corp. (FDX) Q2 2021 Earnings Call

FedEx Corp. (NYSE: FDX) Q2 2021 earnings call dated Dec. 17, 2020

Corporate Participants:

Mickey Foster — Vice President, Investor Relations

Frederick W. Smith — Chairman of the Board and Chief Executive Officer

Brie Carere — Executive Vice President, Chief Marketing and Communications Officer

Rajesh Subramaniam — President and Chief Operating Officer

Mike Lenz — Executive Vice President and Chief Financial Officer

Henry J. Maier — FedEx Ground President and Chief Executive Officer

Donald F. Colleran — FedEx Express President and Chief Executive Officer

Analysts:

David Ross — Stifel Nicolaus — Analyst

Brandon Oglenski — Barclays Capital — Analyst

Bascome Majors — Susquehanna International Group — Analyst

Scott Schneeberger — Oppenheimer & Co. Inc. — Analyst

Amit Mehrotra — Deutsche Bank — Analyst

Thomas Wadewitz — UBS — Analyst

Jack Atkins — Stephens Inc. — Analyst

Jordan Alliger — Goldman Sachs — Analyst

Scott Group — Wolfe Research, LLC — Analyst

Duane Pfennigwerth — Evercore ISI — Analyst

Allison Landry — Credit Suisse — Analyst

Brian Ossenbeck — JPMorgan — Analyst

Allison Poliniak — Wells Fargo Securities — Analyst

David Vernon — Sanford C. Bernstein — Analyst


_______

To read the full earnings call transcript, click here

Most Popular

Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings

After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform

What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top